Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation

This manuscript explores the innovative application of nanotechnology in the diagnosis and treatment of hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide. Emphasizing the synergistic potential of nanotechnology, the paper discusses advanced nanomaterials and techniques, such as targeted drug delivery systems, nanoparticle-based imaging, and multi-modal therapy, which enhance the precision and efficacy of HCC interventions. Nanotechnology offers significant improvements in early diagnosis through enhanced imaging capabilities and tumor-specific biomarkers, enabling more accurate detection of HCC at its early stages. Furthermore, it enables the development of novel therapeutic strategies, including the targeted delivery of chemotherapeutic agents, gene therapies, and immunotherapies, minimizing side effects and improving patient outcomes. The manuscript also highlights challenges such as bio-barrier penetration, biocompatibility, and the high production costs associated with nanomedicine. Despite these obstacles, the integration of nanotechnology with artificial intelligence and personalized medicine promises a transformative future for HCC treatment. This review underscores the pivotal role of nanotechnology in advancing both the diagnostic and therapeutic landscapes for HCC, offering a new frontier for improving survival rates and quality of life for patients.